ER positive
Showing 1 - 25 of >10,000
Assessed by 18F-FES PET/CT in MBC With ER-positive Primary Tumor
Recruiting
- Breast Cancer
-
Shanghai, Shanghai, ChinaBiyun Wang, MD
Apr 5, 2023
Estrogen Receptor Positive Breast Cancer Trial in Edmonton (Estradiol)
Active, not recruiting
- Estrogen Receptor Positive Breast Cancer
-
Edmonton, Alberta, CanadaCross Cancer Institute
Feb 1, 2023
HER2 Status and pCR Rate in ER-positive Breast Cancer Receiving
Completed
- Breast Neoplasms
- NET or NCT
-
Haidian, Beijing, ChinaPeking University Cancer Hospital
Dec 30, 2022
Breast Cancer, Triple Negative Breast Cancer Trial in Gothenburg (Imatinib 400 MG Oral Tablet)
Not yet recruiting
- Breast Cancer
- Triple Negative Breast Cancer
- Imatinib 400 MG Oral Tablet
-
Gothenburg, SwedenBarbro Linderholm
Feb 1, 2023
Gut and Tumor Microbiome in Advanced ER-positive and
Not yet recruiting
- Breast Cancer
- Melanoma
- Observation
- (no location specified)
Nov 6, 2023
Breast Cancer, Cancer of the Breast Trial in Saint Louis (VENTANA MIB-1 Ki67 assay, Oncotype DX® Recurrence Score, PAM50-based
Not yet recruiting
- Breast Cancer
- Cancer of the Breast
- VENTANA MIB-1 Ki67 assay
- +4 more
-
Saint Louis, MissouriWashington University School of Medicine
Apr 18, 2023
Premenopausal Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer Trial in Taipei City (Goserelin, Fulvestrant,
Recruiting
- Premenopausal Breast Cancer
- +2 more
- Goserelin
- +3 more
-
Taipei City, TaiwanDepartment of Oncology, National Taiwan University Hospital
Feb 7, 2023
Breast Tumors Trial in Shanghai (Epirubicin, Docetaxel, cyclophosphamide)
Completed
- Breast Neoplasms
- Epirubicin
- +2 more
-
Shanghai, Shanghai, ChinaRuijin Hospital
Oct 26, 2022
Older Women With ER Positive, HER2 Negative Early Breast Cancer
Enrolling by invitation
- Breast Cancer Female
- Translational study
-
Sutton, United KingdomThe Royal Marsden NHS Foundation Trust
Feb 8, 2023
Breast Cancer Trial (Ovarian Function Suppression + Aromatase Inhibitor, Adjuvant Chemotherapy + Ovarian Function Suppression)
Not yet recruiting
- Breast Cancer
- Ovarian Function Suppression + Aromatase Inhibitor
- Adjuvant Chemotherapy + Ovarian Function Suppression
- (no location specified)
May 19, 2023
ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer, a Germline or Somatic BRCA Mutation, or a
Recruiting
- ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer
- a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status
- Durvalumab
- +2 more
-
Montpellier, France
- +1 more
Nov 16, 2022
ER+, HER2- Advanced Breast Cancer, Metastatic Breast Cancer Trial in Luoyang, Shanghai (TFX06 tablet)
Recruiting
- ER+, HER2- Advanced Breast Cancer
- Metastatic Breast Cancer
- TFX06 tablet
-
Luoyang, Henan, China
- +1 more
Jun 25, 2023
ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Cancer Trial in Madison, Milwaukee (Onapristone, Fulvestrant)
Recruiting
- ER-positive Breast Cancer
- +2 more
-
Madison, Wisconsin
- +1 more
Jul 7, 2022
Breast Cancer, ER Positive Breast Cancer Trial in Lebanon (Letrozole 2.5mg)
Recruiting
- Breast Cancer
- ER Positive Breast Cancer
- Letrozole 2.5mg
-
Lebanon, New Hampshire
- +1 more
Dec 19, 2022
Advanced or Metastatic Breast Cancer Trial in Paris (Milademetan, Patient Reported Outcomes (PROs) and Health-Related Quality of
Not yet recruiting
- Advanced or Metastatic Breast Cancer
- Milademetan
- Patient Reported Outcomes (PROs) and Health-Related Quality of Life (HRQOL)
-
Paris, FranceInstitut Curie
Jun 27, 2023
Breast Cancer Trial in Beijing (18F-FES PET/CT scan)
Recruiting
- Breast Cancer
- 18F-FES PET/CT scan
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Nov 4, 2022
ER-Positive Breast Cancer, HER2-negative Breast Cancer Trial in Houston (Fulvestrant Run-In, No Fulvestrant Run-In)
Recruiting
- ER-Positive Breast Cancer
- HER2-negative Breast Cancer
- Fulvestrant Run-In
- No Fulvestrant Run-In
-
Houston, TexasHouston Methodist Cancer Center
Mar 23, 2022
TNBC - Triple-Negative Breast Cancer Trial (Alkaline Glucosodiene Molecules)
Not yet recruiting
- TNBC - Triple-Negative Breast Cancer
- Alkaline Glucosodiene Molecules
- (no location specified)
Jul 14, 2023
ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer Trial (Elacestrant, Tamoxifen, Letrozole 2.5mg)
Not yet recruiting
- ER-positive Breast Cancer
- +3 more
- Elacestrant
- +4 more
- (no location specified)
Aug 22, 2022
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Trial (Giredestrant, Fulvestrant, Abemaciclib)
Not yet recruiting
- Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Giredestrant
- +6 more
- (no location specified)
Sep 26, 2023